Haier Biotech announced that the company launched a share repurchase program in January 2025 and is expected to repurchase 100 million yuan to 200 million yuan for employee stock ownership plans or equity incentives. As of December 31, 2025, the company has repurchased a total of 3,0553,800 shares, accounting for 0.9604% of the total share capital, and paid a total capital of 98.90.42 million yuan. The repurchase price was 29.86 yuan/share - 34.69 yuan/share. This repurchase complies with the relevant regulations and plans, and the company will continue to advance in accordance with the regulations.

Haier Biotech announced that the company launched a share repurchase program in January 2025 and is expected to repurchase 100 million yuan to 200 million yuan for employee stock ownership plans or equity incentives. As of December 31, 2025, the company has repurchased a total of 3,0553,800 shares, accounting for 0.9604% of the total share capital, and paid a total capital of 98.90.42 million yuan. The repurchase price was 29.86 yuan/share - 34.69 yuan/share. This repurchase complies with the relevant regulations and plans, and the company will continue to advance in accordance with the regulations.